GSK3145095 RIP1 Kinase inhibitor RGNCY-0109
Per 10 mg
GSK3145095 is an inhibitor of RIP1 which regulates cell death and inflammation playing an important role contributing to a variety of human pathologies including immune-mediated inflammatory disease and cancer. GSK3145095 binds specifically and potently to RIP1 and significantly blocks RIP1 kinase-dependent cellular responses. GSK3145095 also promotes tumor suppressive T cell phenotype in pancreatic adenocarcinoma organ cultures further demonstrating its potential as a novel cancer therapy. GSK3145095 is currently in Phase 1 clinical trial for pancreatic adenocarcinoma and a number of other sold tumors.
Systematic Name: (S)-5-benzyl-N-(7,8-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide
Mol Wt: 397.39
Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer. Harris, PA et al. ACS Med Chem Lett. 2019 May 9;10(6):857-862.
There are no uploaded files